The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled Trial
Abstract
Women with oligomenorrhea and polycystic ovaries show a high incidence of ovulation failure perhaps linked to insulin resistance and related metabolic features. A number of reports show that the biguanide metformin improves ovarian function. However, in these trials the quality of evidence supporting ovulation is suboptimal, and few studies have been placebo-controlled. The aim of our study was to use a double-blind, placebo-controlled approach with detailed assessment of ovarian activity (two blood samples per week) to assess the validity of this therapeutic approach in this group of women. Of the 94 patients randomized, 2 withdrew before treatment commenced, 47 received placebo, and 45 received metformin (850 mg, twice a day). The numbers discontinuing the study prematurely were higher in the treatment group (n = 15) than the placebo group (n = 5; P < 0.05). The ovulation frequency assessed by the ratio of luteal phase weeks to observation weeks was significantly (P < 0.01) higher in the treated group (23%) compared with the placebo (13%), and the time to first ovulation was significantly (P < 0.05) shorter [23.6 d; 95% confidence interval (CI), 17, 30; compared with 41.8 d; 95% CI, 28, 56]. The proportion of patients failing to ovulate during the placebo-treatment period was higher (P < 0.05) in the placebo group, and the majority of ovulations were characterized by normal progesterone concentrations in both groups. The effect of metformin on follicular maturation was rapid, because the E2 circulating concentration increased over the first week of treatment only in the metformin group. Significant (P < 0.01) weight loss (and leptin reduction) was recorded in the metformin group, whereas the placebo group actually increased weight (P < 0.05). A significant increase in circulating high-density lipoprotein was observed only in the metformin-treated group. Metabolic risk factor benefits of metformin treatment were not observed in the morbidly obese subgroup of patients (body mass index > 37). No change in fasting glucose concentrations, fasting insulin, or insulin responses to glucose challenge was recorded after 14-wk metformin or placebo therapy. There was an inverse relationship between body mass and treatment efficacy. We show in a large randomized placebo-controlled trial that metformin treatment improves ovulation frequency in women with abnormal ovarian function and polycystic ovaries significantly but to a modest degree, and protracted treatment improves cardiovascular risk factors. These data support a beneficial effect of metformin in improving ovarian function in women with oligomenorrhea and polycystic ovaries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“ipidemia (4, 5) and glucose intolerance (6).”
Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.
Adams, J., Polson, D. W., & Franks, S. (1986) · BMJ · doi:10.1136/bmj.293.6543.355 · Cited by 981
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789 · cited 1×
“Furthermore, we also suggest that the problems of maternal obesity be carefully considered with such treatment, and that weight loss may be the better approach (25) in many circumstances.”
BackgroundNestler, J. E., Jakubowicz, D. J., Evans, W. S., & Pasquali, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382603 · Cited by 784
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Azziz, R., Ehrmann, D., Legro, R. S., Whitcomb, R. W., Hanley, R., Fereshetian, A. G., O’Keefe, M., & Ghazzi, M. N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7375 · Cited by 517
Azziz, R. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1626 · Cited by 376
Nestler, J. E., & Jakubowicz, D. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4431 · Cited by 368
Ehrmann, D. A., Cavaghan, M. K., Imperial, J., Sturis, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3722 · Cited by 336
Cited by
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Franks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw025 · Cited by 705
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Obesity and reproductive disorders in women
Pasquali, R. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg024 · Cited by 539
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
“Metformin has been shown in numerous trials to have a significant effect on dyslipidemia [84,85].”
BackgroundPalomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Glueck, C. J., Papanna, R., Wang, P., Goldenberg, N., & Sieve-Smith, L. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00104-5 · Cited by 399
Ovulation induction in the management of anovulatory polycystic ovary syndrome
Balen, A. H. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.10.008 · Cited by 347
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
Clomiphene citrate—end of an era? a mini-review
Homburg, R. (2005) · Human Reproduction · doi:10.1093/humrep/dei042 · Cited by 331
The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome
Blank, S. K., McCartney, C. R., & Marshall, J. C. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml017 · Cited by 301
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub6 · Cited by 296
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
De Leo, V., la Marca, A., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 286
Palomba, S., Orio, F., Falbo, A., Manguso, F., Russo, T., Cascella, T., Tolino, A., Carmina, E., Colao, A., & Zullo, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0110 · Cited by 279
Hoeger, K. M., Kochman, L., Wixom, N., Craig, K., Miller, R. K., & Guzick, D. S. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.104 · Cited by 278
Hoeger, K., Davidson, K., Kochman, L., Cherry, T., Kopin, L., & Guzick, D. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0461 · Cited by 256
Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome
Harborne, L., Fleming, R., Lyall, H., Norman, J., & Sattar, N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13493-9 · Cited by 256
Self-citationMeta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
Placental passage of metformin in women with polycystic ovary syndrome
Vanky, E., Zahlsen, K., Spigset, O., & Carlsen, S. M. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.051 · Cited by 245
Morin-Papunen, L., Rantala, A. S., Unkila-Kallio, L., Tiitinen, A., Hippeläinen, M., Perheentupa, A., Tinkanen, H., Bloigu, R., Puukka, K., Ruokonen, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3061 · Cited by 243
Costello, M. F., & Eden, J. A. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04554-5 · Cited by 224
Palomba, S., Orio, F., Nardo, L. G., Falbo, A., Russo, T., Corea, D., Doldo, P., Lombardi, G., Tolino, A., Colao, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0689 · Cited by 177
Rachoń, D., & Teede, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.026 · Cited by 161
The management of insulin resistance in polycystic ovary syndrome
Teede, H. J., Hutchison, S. K., & Zoungas, S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.08.001 · Cited by 135
Karimzadeh, M. A., & Javedani, M. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.02.078 · Cited by 118
Lord, J., Thomas, R., Fox, B., Acharya, U., & Wilkin, T. (2006) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.00966.x · Cited by 113
Nieuwenhuis-Ruifrok, A. E., Kuchenbecker, W. K. H., Hoek, A., Middleton, P., & Norman, R. J. (2008) · Human Reproduction Update · doi:10.1093/humupd/dmn043 · Cited by 110
Glueck, C. J., Dharashivkar, S., Wang, P., Zhu, B., Gartside, P. S., Tracy, T., & Sieve, L. (2005) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2005.03.010 · Cited by 99
Fux Otta, C., Wior, M., Iraci, G. S., Kaplan, R., Torres, D., Gaido, M. I., & Wyse, E. P. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903215581 · Cited by 85
Marzouk, T. M., & Sayed Ahmed, W. A. (2015) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2015.01.002 · Cited by 73
Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad098 · Cited by 72
Madsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63
Patel, R., & Shah, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1279597 · Cited by 47
Qublan, H. S., Yannakoula, E. K., Al-Qudah, M. A., & El-Uri, F. I. (2007) · Saudi Medical Journal · doi:10.15537/1658-3175.4126 · Cited by 40
Serum chemerin levels in Polycystic Ovary Syndrome after metformin therapy
Foda, A. A., Foda, E. A., El-Negeri, M. A., & El-Said, Z. H. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.050 · Cited by 27
Kjøtrød, S. B., Sunde, A., von Düring, V., & Carlsen, S. M. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.11.069 · Cited by 22
Bordewijk, E. M., Wang, R., van Wely, M., Costello, M. F., Norman, R. J., Teede, H., Gurrin, L. C., Mol, B. W., & Li, W. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa031 · Cited by 18
Body weight reduction and metformin: Roles in polycystic ovary syndrome
AL-Nozha, O., Habib, F., Mojaddidi, M., & El-Bab, M. F. (2013) · Pathophysiology · doi:10.1016/j.pathophys.2013.03.002 · Cited by 20
Baldani, D. P., Skrgatic, L., Ougouag, R., & Kasum, M. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1381681 · Cited by 17
Sathyapalan, T., Cho, L. W., Kilpatrick, E. S., Coady, A., & Atkin, S. L. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03345.x · Cited by 11
Metadata
- Authors
- Fleming, R.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-02-01
- Volume
- 87
- Issue
- 2
- Pages
- 569-574
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1996445345
- Cited by
- 368
- References
- 26
- FWCI
- 26.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.